astrazeneca
-
An RSV Vaccine From Moderna Passes Phase III Trial Amid Viral Surge
We’re getting ever closer to besting a frequent microscopic source of misery: the respiratory syncytial virus. Late Tuesday, Moderna announced the seemingly successful Phase III trial results of its experimental RSV vaccine. In older adults, the vaccine appeared to be over 80% effective at preventing two or more symptoms linked to lower respiratory infections caused…
-
AstraZeneca Scientist Defends Plan to Start Selling COVID-19 Vaccine For Profit
A scientist who works on the AstraZeneca vaccine with Oxford University in the UK has come out to defend the decision to sell its COVID-19 vaccine at a profit, according to a new report from the Financial Times. AstraZeneca was previously unique because it sold the COVID-19 vaccine at cost, unlike most other vaccine makers…
-
FDA OKs Moderna and Johnson & Johnson Boosters in the U.S., And for People to Mix and Match
On Wednesday night, the U.S. Food and Drug Administration officially authorised the use of boosters for eligible people vaccinated against covid-19 with either the Moderna and Johnson & Johnson vaccine. They’ve also given their blessing for people to mix and match different types of vaccines for their booster — a likely welcome decision for the…
-
UK to Recommend Covid-19 Booster Doses for Older and High-Risk People
New data from the UK suggests that some vaccinated people, particularly seniors, experience a greater loss in protection over time against covid-19 symptoms and severe illness than the general public. The findings were enough for the country’s vaccine experts to recommend booster shots for higher-risk groups, including all adults over 50.